FDA-Drug2026-09-09Class IIPROCESSING DEFECT
Baxter Clindamycin Injection recalled for CGMP manufacturing deviations
What this means
Baxter Healthcare Corporation is recalling one lot of Clindamycin Injection USP in 5% Dextrose (900 mg/50 mL) due to deviations from current good manufacturing practices (CGMP). The affected lot was distributed nationwide, in Puerto Rico, and Chile. No injuries have been reported.
- If you received or administered this medication, check the lot number NC194075 and expiration date 10/29/2027.
- Contact your healthcare provider or pharmacy if you have questions about your supply.
- Do not use this lot; return it to the pharmacy or manufacturer.
The agency's original wording
Hazard
CGMP Deviations
Intended for
Adults
Illnesses reported
None reported
Sold states
US Nationwide; Puerto Rico; and Chile.
Affected count
N/A
Manufactured in
1 Baxter Pkwy, N/A, Deerfield, IL, United States
Products
Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Manufactured by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-4114-50.
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0817-2026More Baxter recalls
- FDA-Device2026-09-09Baxter Novum IQ Syringe Pump recalled for software issue during multi-syringe infusion
- FDA-Device2026-09-09Baxter Novum IQ Syringe Pump recalled for software issue during multi-syringe infusion
- FDA-Drug2026-09-09Baxter Clindamycin Phosphate injection recalled for manufacturing compliance deviations
- FDA-Drug2026-09-09Baxter Vancomycin Injection recalled for CGMP manufacturing deviations
- FDA-Drug2026-09-09Baxter Clindamycin Injection recalled for manufacturing quality deviations
Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.